Arcus Biosciences (RCUS) EBIT (2017 - 2026)
Arcus Biosciences (RCUS) recorded quarterly EBIT of -$134.0 million in Q1 2026, down 17.54% quarter-over-quarter from -$114.0 million in Q4 2025, and down 9.84% on a YoY basis from -$148.6 million in Q1 2025.
Arcus Biosciences (RCUS) EBIT (2017 - 2026) Analysis & Trends
Arcus Biosciences' EBIT history runs 10 years deep, the most recent figure standing at -$134.0 million for Q1 2026.
- In Q1 2026, EBIT fell 9.84% year-over-year to -$134.0 million; the TTM figure through Mar 2026 stood at -$398.0 million (up 8.72% YoY), while the FY2025 annual figure was -$386.0 million, down 16.97% from the prior year.
- EBIT was -$134.0 million for Q1 2026 at Arcus Biosciences, down from -$114.0 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$8.0 million in Q2 2025 to a low of -$142.0 million in Q3 2025.
- Historically, EBIT has averaged -$86.5 million across 5 years, with a median of -$86.0 million in 2023.
- Biggest YoY gain for EBIT was 92.45% in 2025; the steepest drop was 662.5% in 2025.
- A 5-year view of EBIT shows it stood at -$74.0 million in 2022, then slipped by 22.97% to -$91.0 million in 2023, then dropped by 13.19% to -$103.0 million in 2024, then declined by 10.68% to -$114.0 million in 2025, then slipped by 17.54% to -$134.0 million in 2026.
- The last three EBIT figures came in at -$134.0 million (Q1 2026), -$114.0 million (Q4 2025), and -$142.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Arcus Biosciences | 3.05 Bn | 2.23 Bn | - | -134.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -134.00 Mn |
| Dec 31, 2025 | -114.00 Mn |
| Sep 30, 2025 | -142.00 Mn |
| Jun 30, 2025 | -8.00 Mn |
| Mar 31, 2025 | -122.00 Mn |
| Dec 31, 2024 | -103.00 Mn |
| Sep 30, 2024 | -105.00 Mn |
| Jun 30, 2024 | -106.00 Mn |
| Mar 31, 2024 | -16.00 Mn |
| Dec 31, 2023 | -91.00 Mn |
| Sep 30, 2023 | -80.00 Mn |
| Jun 30, 2023 | -83.00 Mn |
| Mar 31, 2023 | -86.00 Mn |
| Dec 31, 2022 | -74.00 Mn |
| Sep 30, 2022 | -70.00 Mn |
| Jun 30, 2022 | -69.00 Mn |
| Mar 31, 2022 | -67.00 Mn |
| Dec 31, 2021 | 281.02 Mn |
| Sep 30, 2021 | -78.14 Mn |
| Jun 30, 2021 | -76.14 Mn |